Patents by Inventor Hiromi MURAOKA

Hiromi MURAOKA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy using azabicyclo compound for cancer
    Patent number: 11918562
    Abstract: Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).
    Type: Grant
    Filed: September 30, 2021
    Date of Patent: March 5, 2024
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiromi Muraoka, Akira Kanoh
  • COMBINATION THERAPY FOR CANCER USING AZABICYCLIC COMPOUND AND POLY(ADENOSINE 5'-DIPHOSPHATE-RIBOSE) POLYMERASE INHIBITOR
    Publication number: 20220280489
    Abstract: Provided is a novel method for treating cancer with a high antitumor effect. The present invention provides an antitumor agent comprising an azabicyclo compound of the following Formula (I) or a salt thereof and a poly(adenosine 5?-diphosphate-ribose) polymerase inhibitor which are administered in combination.
    Type: Application
    Filed: August 5, 2020
    Publication date: September 8, 2022
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiromi MURAOKA, Naoki ARIMURA
  • COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER
    Publication number: 20220016090
    Abstract: Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).
    Type: Application
    Filed: September 30, 2021
    Publication date: January 20, 2022
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiromi MURAOKA, Akira KANOH
  • Combination therapy using azabicyclo compound for cancer
    Patent number: 11166943
    Abstract: Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: November 9, 2021
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiromi Muraoka, Akira Kanoh
  • Combination therapy using azabicyclo compound for cancer
    Patent number: 10849886
    Abstract: Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: December 1, 2020
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiromi Muraoka, Akira Kanoh
  • PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES INVOLVING IDO EXPRESSION
    Publication number: 20200281904
    Abstract: To provide a prophylactic and/or therapeutic agent for diseases involving IDO expression, and a pharmaceutical composition for treating IDO-positive tumors. A prophylactic and/or therapeutic agent for diseases involving IDO expression, comprising an HSP90-inhibiting compound as an active ingredient; and a pharmaceutical composition for treating IDO-positive tumors.
    Type: Application
    Filed: September 14, 2018
    Publication date: September 10, 2020
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Hiromi MURAOKA
  • COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER
    Publication number: 20200276171
    Abstract: Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiromi Muraoka, Akira Kanoh
  • COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER
    Publication number: 20170216261
    Abstract: Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).
    Type: Application
    Filed: April 21, 2017
    Publication date: August 3, 2017
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiromi MURAOKA, Akira KANOH
  • Combination therapy using azabicyclo compound for cancer
    Patent number: 9694001
    Abstract: Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: July 4, 2017
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiromi Muraoka, Akira Kanoh
  • COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER
    Publication number: 20160228417
    Abstract: Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent(s).
    Type: Application
    Filed: September 29, 2014
    Publication date: August 11, 2016
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiromi MURAOKA, Akira KANOH
  • Cover
    Patent number: D792514
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: July 18, 2017
    Assignee: Mark's Group Holdings, Inc.
    Inventors: Hiroaki Takei, Hiromi Muraoka, Meguru Ishida